Stocktoria
PUMA BIOTECHNOLOGY, INC. PBYI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-03-21
PUMA BIOTECHNOLOGY, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $228.4M | $230.5M | $235.6M | $228.0M | $253.2M |
| R&D expense | — | — | — | — | $71.9M |
| SG&A expense | $70.8M | $80.2M | $89.9M | $90.0M | $116.3M |
| Operating income | $37.3M | $31.0M | $32.6M | $23.7M | $1.3M |
| Interest expense | — | — | $13.3M | $11.6M | $12.8M |
| Income tax | $4.7M | -$6.2M | $1.1M | $455,000 | $324,000 |
| Net income | $31.1M | $30.3M | $21.6M | $2,000 | -$29.1M |
| EPS (diluted) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 |
| Operating cash flow | $41.8M | $38.9M | $27.0M | -$15.8M | $20.6M |
| Free cash flow | $41.7M | $38.9M | $26.9M | -$15.8M | $20.6M |
| Cash & equivalents | $29.6M | $69.2M | $84.6M | $76.2M | $63.1M |
| Inventory | $5.5M | $8.7M | $7.1M | $4.5M | $7.1M |
| Total assets | $216.3M | $213.3M | $230.5M | $222.1M | $226.6M |
| Total liabilities | $86.0M | $121.2M | $177.1M | $200.5M | $229.0M |
| Shareholders' equity | $130.3M | $92.1M | $53.4M | $21.6M | -$2.4M |
Source: SEC EDGAR filings · CIK 0001401667 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.